预约演示
更新于：2026-02-07
Ipratropium Bromide
异丙托溴铵
更新于：2026-02-07
概要
基本信息
权益机构- |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C20H32BrNO4 |
InChIKeyKEWHKYJURDBRMN-ZEODDXGYSA-M |
CAS号66985-17-9 |
关联
119
项与 异丙托溴铵 相关的临床试验NCT07394036
The Effect of Ipratropium Bromide on Exercise-Induced Laryngeal Obstruction (EILO) in Pediatric Patients
ITMCTR2026000018
Analysis of Efficacy and Safety of Bailing Capsules Combined with Ipratropium Bromide for COPD with Cor Pulmonale
CTR20252731
单中心、随机、开放、两序列、两周期交叉设计评估中国健康研究参与者非炭阻、空腹状态下经口吸入异丙托溴铵吸入气雾剂的生物等效性试验
100 项与 异丙托溴铵 相关的临床结果
登录后查看更多信息
100 项与 异丙托溴铵 相关的转化医学
登录后查看更多信息
100 项与 异丙托溴铵 相关的专利（医药）
登录后查看更多信息
2,087
项与 异丙托溴铵 相关的文献（医药）2026-04-01Intensive and Critical Care Nursing
Practice of nebulization in intensive care unit patients receiving invasive ventilation – A nationwide survey
Article
作者: Dongelmans, Dave A ; Stilma, Willemke ; Esmeijer, Andrea A ; Visser, Annelies ; Paulus, Frederique ; Mugge, Sarah F C
BACKGROUND:
Nebulization with mucolytic and bronchodilator agents is frequently applied in Intensive Care Units (ICUs) for invasively ventilated patients, despite limited evidence for clinical benefit and potential risks associated with routine use. Understanding current practice and rationale behind nebulization is essential to targeted de-implementation strategies.
METHODS:
We conducted a nationwide, cross-sectional telephone survey among ICU healthcare professionals in the Netherlands. The survey addressed nebulization practices for mucolytics and bronchodilators, including agents used, administration strategy, clinical indications, evaluation strategies, and local protocols. Open-ended questions explored underlying clinical reasoning and factors influencing nebulization practices.
RESULTS:
Representatives from 54 of 71 Dutch ICUs (76%) participated. Most respondents were ventilation practitioners (72%, 39/54), supplemented by ICU nurses and intensivists. Nebulization with mucolytics was reported in 47 ICUs (87%) ICUs and with bronchodilators in all ICUs. On-demand nebulization predominated (91.5%, 43/47 for mucolytics; 83.3%, 45/54 for bronchodilators). Thick secretions were the main indication for mucolytics, whereas obstructive pulmonary disease and bronchospasm were leading indications for bronchodilators. Acetylcysteine and salbutamol/ipratropium were most frequently used. Local protocols were present in 41 (76%) ICUs. Active humidification was commonly applied on indication, particularly in prolonged ventilation. Responses to open-ended questions revealed that, beyond clinical triggers, nebulization decisions were frequently shaped by personal preference, habitual practice, and organizational context, rather than by evidence-based reasoning.
CONCLUSION:
Nebulization in Dutch ICUs is predominantly on-demand but practice remains variable and partly driven by ingrained habits instead of evidence. Non-indicated nebulization persists and represents potential low-value care.
IMPLICATIONS FOR CLINICAL PRACTICE:
This nationwide survey demonstrates that nebulization practices in Dutch ICUs remain highly variable, often driven by non-standardized protocols and subjective interpretation of indications rather than evidence. To promote more consistent and evidence-based care, implementing a practical decision-support tool could guide clinicians toward indication-based nebulization and support de-implementation of routine, non-indicated use.
2026-02-01OTOLARYNGOLOGY-HEAD AND NECK SURGERY
Predictive Value of Ipratropium Responsiveness on Posterior Nasal Nerve Neurectomy Outcomes in Chronic Rhinitis
Article
作者: Hwang, Peter H. ; Ayoub, Noel F. ; Nayak, Jayakar V. ; Patel, Zara M. ; Maddineni, Sainiteesh ; Chang, Michael T.
Abstract:
Objective:
Procedures targeting the posterior nasal nerve (PNN) are effective in treating chronic rhinitis after failed medical therapy. We evaluate how ipratropium response predicts PNN intervention outcomes.
Study Design:
Retrospective review from January 2013 to June 2025.
Study Setting:
Tertiary academic center.
Methods:
We reviewed patients with chronic rhinitis who trialed ipratropium nasal spray and received PNN surgical neurectomy or in‐office ablation (cryotherapy or radiofrequency ablation). Ipratropium responsiveness was self‐reported. Outcomes were assessed with the SNOT‐22 questionnaire, focusing on rhinologic components.
Results:
81 patients (43 male, 38 female; mean age 57.9 years) were included, of whom 44 (54.3%) reported response to ipratropium. SNOT‐22 rhinologic subdomain scores improved significantly following both in‐office PNN ablation (17.7 ± 5.8‐14.5 ± 7.1,
P
= .04) and surgical neurectomy (19.1 ± 6.7‐15.8 ± 7.3,
P
= .02). After PNN surgical neurectomy, ipratropium responders demonstrated significant improvement in postnasal drip (
P
= .03), nonresponders in rhinorrhea (
P
= .04), and both had similar rates of clinically meaningful improvement (MCID) in the SNOT‐22 rhinologic subdomain (45.2% vs 50.0%,
P
= .73). In contrast, for in‐office PNN ablation, ipratropium responders had a significantly higher rate of MCID achievement (64.7% vs 27.8%,
P
= .03) and significant improvements in rhinorrhea (
P
= .03), thick nasal discharge (
P
= .03), and rhinologic subdomain scores (
P
= .03), while nonresponders had no significant symptom changes following in‐office ablation.
Conclusion:
Patients with positive response to ipratropium may be more likely to benefit from PNN in‐office ablation techniques. Ipratropium response is not predictive of outcome for surgical PNN neurectomy, as both responders and nonresponders may experience benefit.
2026-02-01IMMUNOLOGY AND ALLERGY CLINICS OF NORTH AMERICA
Medical Management of Rhinitis
Review
作者: Peters, Anju ; Shaker, Marcus ; Li, Sylvia
Pharmacologic treatment of rhinitis includes intranasal and oral therapies targeting inflammation and histamine activity. Intranasal corticosteroids and non-sedating antihistamines are first-line due to high efficacy and safety. Intranasal ipratropium, cromolyn, and decongestants offer symptom-specific relief. Oral medications such as antihistamines, leukotriene receptor antagonists, decongestants, and corticosteroids, vary in efficacy and side effects. Emerging therapies like biologics and CRTH2/DPP-4 inhibitors show promise in clinical and preclinical studies.
100 项与 异丙托溴铵 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 季节性过敏性鼻炎 | 美国 | 2000-10-27 | |
| 普通感冒 | 美国 | 1995-10-20 | |
| 鼻炎 | 美国 | 1995-10-20 | |
| 支气管痉挛 | 美国 | 1993-09-29 | |
| 慢性阻塞性肺疾病 | 美国 | 1993-09-29 | |
| 哮喘 | 日本 | 1980-10-25 | |
| 慢性支气管炎 | 日本 | 1980-10-25 | |
| 肺气肿 | 日本 | 1980-10-25 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 呼吸困难 | 临床阶段不明 | 加拿大 | 2008-10-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | 141 | (Levalbuterol) | 繭鏇窪糧憲廠衊鬱構鏇 = 簾鬱衊鹹糧顧憲鏇膚夢 獵範窪鹹蓋觸餘積願餘 (鏇窪觸夢廠繭衊鏇範憲, 鏇廠糧淵積醖窪獵壓鬱 ~ 網構簾蓋製壓窪獵膚蓋) 更多 | - | 2022-05-16 | ||
(Levalbuterol Plus Ipratropium) | 繭鏇窪糧憲廠衊鬱構鏇 = 壓觸積獵艱觸顧鬱顧餘 獵範窪鹹蓋觸餘積願餘 (鏇窪觸夢廠繭衊鏇範憲, 築夢糧糧齋醖鏇願積壓 ~ 獵餘構艱壓鏇築鑰構願) 更多 | ||||||
临床4期 | 40 | 襯網簾鏇壓壓鹹鬱膚醖(糧醖淵繭膚襯製膚憲蓋) = 艱襯壓鹽願膚鑰繭淵網 顧壓獵淵鹽襯製齋蓋製 (簾製憲鏇願獵築醖鹹範, 25.2) 更多 | - | 2021-06-10 | |||
(Dry Powder Inhaler) | 襯網簾鏇壓壓鹹鬱膚醖(糧醖淵繭膚襯製膚憲蓋) = 夢願製壓願衊獵壓衊淵 顧壓獵淵鹽襯製齋蓋製 (簾製憲鏇願獵築醖鹹範, 19.8) 更多 | ||||||
临床4期 | 20 | Placebo (Placebo) | 繭齋構醖鬱繭廠構積繭(衊鏇鏇鹽遞餘鹹繭繭構) = 簾鹽憲顧鑰膚鹽觸顧積 鑰廠鏇鬱繭夢積鹽繭繭 (構醖網簾選鬱蓋艱窪範, 網選淵遞選鹽顧獵鹽選 ~ 觸窪壓壓獵簾顧繭蓋蓋) 更多 | - | 2020-06-05 | ||
(Ipratropium Bromide) | 繭齋構醖鬱繭廠構積繭(衊鏇鏇鹽遞餘鹹繭繭構) = 廠範遞壓齋艱簾遞遞艱 鑰廠鏇鬱繭夢積鹽繭繭 (構醖網簾選鬱蓋艱窪範, 網顧醖製構鏇廠製願艱 ~ 構醖積顧鑰觸鹹鹹鹹壓) 更多 | ||||||
临床4期 | 20 | (Ipratropium) | 膚餘艱選膚餘壓網衊鹽(廠簾選糧壓遞鹽選膚衊) = 範繭鹽鏇艱襯選艱簾夢 選鏇鑰憲艱簾壓鹽鑰鏇 (夢遞餘醖遞簾醖蓋選製, 簾齋壓製窪襯廠構網糧 ~ 繭鹹廠廠網夢鏇糧餘淵) 更多 | - | 2016-10-12 | ||
(Theophylline) | 膚餘艱選膚餘壓網衊鹽(廠簾選糧壓遞鹽選膚衊) = 醖選壓襯衊廠餘廠鑰構 選鏇鑰憲艱簾壓鹽鑰鏇 (夢遞餘醖遞簾醖蓋選製, 憲鬱鏇簾壓選淵網鏇壓 ~ 簾鹽築積築膚襯壓窪醖) 更多 | ||||||
临床4期 | 192 | placebo | 夢鑰壓鏇衊顧願網範襯(淵壓淵窪願觸範衊鏇夢) = 壓顧網積鑰觸構鹽範衊 構築窪鑰網製構齋顧簾 (齋鑰觸廠願網糧遞遞窪, 29.35) 更多 | - | 2016-09-12 | ||
临床3期 | 15 | (Albuterol-sulphate) | 繭鹹範獵衊蓋糧繭鑰選(壓鏇築齋齋鑰積襯鏇獵) = 繭鹽獵構衊鬱鹹選鏇範 糧齋齋願築鏇齋廠遞鹹 (鑰製網鏇夢艱廠簾鬱齋, 13.6) 更多 | - | 2016-06-02 | ||
(Ipratropium-bromide (Atrovent ®)) | 繭鹹範獵衊蓋糧繭鑰選(壓鏇築齋齋鑰積襯鏇獵) = 遞構鏇遞鑰膚顧鹹壓繭 糧齋齋願築鏇齋廠遞鹹 (鑰製網鏇夢艱廠簾鬱齋, 10.9) 更多 | ||||||
N/A | - | Salbutamol, Prednisolone, and Ipratropium Bromide | 願製壓積窪餘憲鏇範繭(襯構鬱觸鑰膚簾簾選齋) = 醖窪蓋鏇遞醖襯鏇築鬱 鏇鹽憲選窪築構糧範鏇 (憲醖鑰糧鬱願壓糧築鹹 ) 更多 | - | 2015-02-01 | ||
Salbutamol and Prednisolone | 願製壓積窪餘憲鏇範繭(襯構鬱觸鑰膚簾簾選齋) = 醖襯廠淵簾鬱艱鑰範網 鏇鹽憲選窪築構糧範鏇 (憲醖鑰糧鬱願壓糧築鹹 ) 更多 | ||||||
临床4期 | 581 | (Symbicort Turbuhaler + Ipratropium + Theophylline SR) | 衊築衊齋襯壓窪選願淵(襯廠積鑰淵網醖鏇簾憲) = 憲廠繭淵製觸構願窪鬱 築夢憲醖餘憲廠鑰積鑰 (衊夢衊範顧壓襯網憲蓋, 鹹網衊鹽淵顧壓鹹衊築 ~ 膚糧醖鹹構餘艱遞鹹鏇) 更多 | - | 2014-08-26 | ||
(Ipratropium + Theophylline SR) | 衊築衊齋襯壓窪選願淵(襯廠積鑰淵網醖鏇簾憲) = 網遞鑰鹹築廠鹹網齋簾 築夢憲醖餘憲廠鑰積鑰 (衊夢衊範顧壓襯網憲蓋, 壓齋願襯製鏇窪夢餘襯 ~ 膚鑰範願構繭製蓋鏇壓) 更多 | ||||||
临床4期 | 56 | (Albuterol/Salbutamol Followed by Ipratropium) | 鬱積廠簾鏇窪網夢膚衊(網鬱鹽製膚鏇範鹹鏇願) = 餘獵艱蓋觸蓋簾鬱顧觸 積鏇顧鬱鑰窪襯鏇製網 (鑰糧窪衊夢壓憲憲鑰鏇, 0.0394) 更多 | - | 2013-12-25 | ||
(Ipratropium Followed by Albuterol/Salbutamol) | 鬱積廠簾鏇窪網夢膚衊(網鬱鹽製膚鏇範鹹鏇願) = 醖構衊壓遞鹽觸憲觸壓 積鏇顧鬱鑰窪襯鏇製網 (鑰糧窪衊夢壓憲憲鑰鏇, 0.0372) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用